Big Pharma · Immunology · United States

AstraZeneca — Immunology in United States

OncologyRare DiseaseImmunologyCardiometabolic
Commission a AstraZeneca report

AXLRx AstraZeneca intelligence — Immunology in United States: 1 report covering Immunology in United States.

All areas NeurologyImmunologyMetabolicOncologyRare Disease
Market: All United States
Market access — United States

Tagrisso dominant in first-line EGFR+ NSCLC; Alexion complement franchise (Ultomiris/Soliris) holds strong specialty access.

AXLRx reports featuring AstraZeneca — Immunology in United States
Atopic Dermatitis
CI
CI Immunology CI TeamLaunch Lead

US Atopic Dermatitis Competitive Intelligence

Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs.

US In-Market Read report →